Each November, we commemorate National Epilepsy Awareness Month (NEAM), focusing on educating the public about epilepsy symptoms and supporting research efforts. In honor of NEAM, today’s article will focus on epilepsy. According to the Centers for Disease Control (CDC), between 2021 and 2022, approximately 2.9 million adults aged 18 and older reported experiencing active epilepsy, representing about 1% of all adults in the United States (US).


This article will explore the most recent guidelines on epilepsy provided by various medical societies. The release of the Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After in Utero Exposure to Antiseizure Medication Guideline has led to the approval of a new medication for the treatment of a rare form of epilepsy. The focus of this article will be on these guidelines and the recent update from the FDA.

Part 1 – Part 1 – Current Epilepsy Guidelines

To start, here is a listing of the recently published epilepsy guidelines in the US:

Part 2 – Recent FDA Approvals

Below, is the recent medication recently approved by the FDA that we anticipate being incorporated into future US guidelines:

  • Libervant™ (diazepam)
    • Aquestive Therapeutics, Inc.
    • FDA Approved in April 2024
    • Libervant Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy between 2 to 5 years of age.

Thank you for taking the time to review the current epilepsy guidelines, as well as the recent major changes and FDA approvals that have recently occurred. We value your feedback and would like to hear your suggestions for future topics to be covered in our guideline series. Please feel free to contact us with any ideas or questions you may have.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2024 Guideline Central, All rights reserved.